Bristol Addresses Serzone/Seroquel Mix-Ups With Patient Information Leaflet
Executive Summary
Bristol-Myers Squibb will distribute Serzone patient information leaflets with each prescription of the anti-depressant, to address medication mix-ups with AstraZeneca's anti-psychotic Seroquel
You may also be interested in...
Color-Coded Rx Packaging Could Reduce Errors; Method Requires Study
Color-coded drug packaging and labeling could help reduce medication errors in certain circumstances, but the method requires testing prior to adoption, participants at a March 7 FDA public hearing said
Color-Coded Rx Packaging Could Reduce Errors; Method Requires Study
Color-coded drug packaging and labeling could help reduce medication errors in certain circumstances, but the method requires testing prior to adoption, participants at a March 7 FDA public hearing said
Bristol Serzone Status Unchanged In U.S.; Antidepressant Pulled In Europe
FDA is comfortable with Serzone's current labeling, the agency said following Bristol-Myers Squibb's decision to pull the antidepressant off the market in Europe